SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
RANDALL PATRICIA

(Last) (First) (Middle)
C/O OXFORD IMMUNOTEC GLOBAL PLC
94C INNOVATION DRIVE

(Street)
ABINGDON, OXFORDSHIRE X0 OX14 4RZ

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Oxford Immunotec Global PLC [ OXFD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
03/08/2021
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 03/08/2021 D 27,805 D $22(1) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $0.81 03/08/2021 D 11,931 (2) 11/06/2022 Ordinary Shares 11,931 $21.19(3) 0 D
Stock Option (Right to Buy) $0.18 03/08/2021 D 10,310 (2) 12/31/2021 Ordinary Shares 10,310 $21.82(3) 0 D
Stock Option (Right to Buy) $8.65 03/08/2021 D 7,457 (2) 06/28/2026 Ordinary Shares 7,457 $13.35(3) 0 D
Stock Option (Right to Buy) $14.46 03/08/2021 D 7,457 (2) 06/06/2027 Ordinary Shares 7,457 $7.54(3) 0 D
Stock Option (Right to Buy) $14.49 03/08/2021 D 7,457 (2) 06/19/2028 Ordinary Shares 7,457 $7.51(3) 0 D
Stock Option (Right to Buy) $14.44 03/08/2021 D 7,457 (2) 06/18/2029 Ordinary Shares 7,457 $7.56(3) 0 D
Stock Option (Right to Buy) $16.86 03/08/2021 D 14,914 (2) 06/12/2024 Ordinary Shares 14,914 $5.14(3) 0 D
Stock Option (Right to Buy) $16.86 03/08/2021 D 7,457 (2) 06/12/2024 Ordinary Shares 7,457 $5.14(3) 0 D
Stock Option (Right to Buy) $14.17 03/08/2021 D 7,457 (2) 06/09/2025 Ordinary Shares 7,457 $7.83(3) 0 D
Stock Option (Right to Buy) $12.96 03/08/2021 D 9,494 (2) 06/24/2030 Ordinary Shares 9,494 $9.04(3) 0 D
Explanation of Responses:
1. Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
2. In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price.
3. Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price.
/s/ Matthew T E McLaughlin, as Attorney-in-Fact for Patricia Randall 03/12/2021
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.